{"id":"tp-34773","type":"article-newspaper","title":"Disc Medicine's Bitopertin Meets Both Primary Goals in Phase 3 Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/34773","datePublished":"2026-10-19T12:35:36.000Z","dateModified":"2026-10-19T12:35:36.000Z","language":"en","abstract":"The 183-patient trial tested the drug in two rare blood disorders. Disc Medicine plans to resubmit its FDA application by the end of 2026.","section":"Business","references":[]}